AstraZeneca and Trump Administration Reach Agreement to Lower Drug Prices

AstraZeneca has agreed to lower drug prices for Medicaid by adopting most-favored-nation pricing, matching the lowest prices in developed countries, as part of a deal with the Trump administration aimed at reducing U.S. prescription drug costs. This follows similar agreements with Pfizer and is part of broader efforts to curb drug prices through executive actions and new government initiatives.